第十一届董事会第二十七次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）第十一届董事 会第二十七次会议于 2025 年 8 月 25 日以通讯表决方式召开。本次会议于 2025 年 8 月 15 日以电子邮件等方式送达了会议通知。会议应到董事 7 人，实到董事 7 人，会议的召开符合《公司法》和《公司章程》有关规定。审议通过了如下议 案： 一、 审议通过了《 2025 年半年度报告全文及摘要的议案》 《2025 年半年度报告摘要》同日刊载于《上海证券报》《证券日报》及巨潮 资讯网（http://www.cninfo.com.cn）；《2025 年半年度报告全文》同日刊载于 巨潮资讯网（http://www.cninfo.com.cn）。 表决结果：7 票同意，0 票反对，0 票弃权 二、审议通过了《关于新兴际华集团财务有限公司的风险持续评估报告》 根据《深圳证券交易所股票上市规则》相关规定，本次交易构成关联交易， 王建平先生、封多佳先生系关联董事，已回避本议案的表决。 证券代码：000566 证 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥450,274,958.78, a decrease of 24.12% compared to ¥593,434,411.11 in the same period last year[22]. - The net loss attributable to shareholders was ¥158,307,106.28, an improvement from a loss of ¥200,309,364.53 in the previous year[22]. - The net cash flow from operating activities was ¥32,042,086.77, a significant recovery from a negative cash flow of ¥57,082,574.57 in the same period last year[22]. - Total assets at the end of the reporting period were ¥5,979,593,642.44, down 2.19% from ¥6,113,528,499.69 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 30.25% to ¥366,375,180.92 from ¥525,286,982.84 at the end of the previous year[22]. - The weighted average return on net assets was -35.53%, a decline of 25.32% compared to -10.21% in the previous year[22]. - The company's revenue for the reporting period was ¥450,274,958.78, a decrease of 24.12% compared to ¥593,434,411.11 in the same period last year[58]. - The company's operating costs decreased by 17.94%, amounting to ¥322,850,103.04, down from ¥393,444,076.44 year-on-year[58]. - Sales expenses were reduced by 41.18%, totaling ¥85,922,946.64, primarily due to effective control of market development costs during the reporting period[58]. - Management expenses increased by 38.54%, reaching ¥110,802,084.31, attributed to intangible asset amortization in the current reporting period[58]. - Revenue from the pharmaceutical sector dropped by 29.43% to ¥353,241,345.87, accounting for 78.45% of total revenue[62]. - Revenue from medical services increased by 8.42% to ¥83,732,699.22, representing 18.60% of total revenue[62]. - The company's total assets increased to CNY 6.63 billion in the first half of 2025, up from CNY 6.31 billion in the first half of 2024[184]. - Total liabilities rose to CNY 4.32 billion in the first half of 2025, compared to CNY 3.91 billion in the same period last year, reflecting a 10.7% increase[184]. - The equity attributable to shareholders of the parent company decreased to CNY 2.32 billion in the first half of 2025 from CNY 2.40 billion in the first half of 2024[184]. - The company reported a net profit of 2.1 billion, which is a decrease from 2.2 billion in the same period last year[200]. Market and Product Development - The pharmaceutical manufacturing industry saw a revenue decline of 1.2% year-on-year, with total revenue of ¥12,275.2 billion in the first half of 2025[30]. - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The company reported non-operating income of ¥22,283,399.71 after tax, primarily from government subsidies and asset disposals[26][28]. - In the first half of 2025, the company focused on enhancing integrated capabilities, leading to improved operational quality across R&D, products, market, and management[34]. - The company accelerated the development of innovative drugs, with a breakthrough treatment for liver fibrosis included in the list of breakthrough therapies and currently undergoing Phase III clinical trials[34]. - The company achieved consistency evaluation for three specifications of injectable cefoperazone sodium and completed registration for injectable meropenem[34]. - The company expanded its product offerings in the health sector, launching New Zealand AFT health products and entering the Malaysian market with traditional Chinese medicine products[35]. - The company is actively participating in national and local drug procurement, with 700 varieties expected to be included in the procurement process in 2025[32]. - The company has signed agreements for three new contract manufacturing enterprises and one volume-based product processing agreement in the first half of 2025[36]. - The company is enhancing its market presence through academic promotions and e-commerce channels, achieving breakthroughs in national procurement projects[35]. - The company is focusing on a full industry chain development model centered on anti-infection drugs, with R&D centers established in multiple locations including Haikou and Chongqing[52]. - The company is actively developing new products in the fields of anti-infection, neurological, digestive, cardiovascular, and metabolic diseases[52]. - The company plans to invest 100 million CNY in R&D for innovative drug formulations over the next two years, aiming to diversify its product offerings[48]. - The company is focusing on new product development, with a commitment to invest in research and technology to enhance its product offerings[135]. Strategic Initiatives and Future Outlook - The company provided an optimistic outlook for the second half of 2025, projecting a revenue growth of 10% to 12% based on new product launches and market expansion strategies[43]. - New product development includes the introduction of a novel antibiotic, which is expected to contribute an additional 200 million CNY in revenue by the end of 2025[48]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2026[49]. - A strategic acquisition of a local pharmaceutical firm is anticipated to enhance the company's product portfolio and increase market competitiveness[49]. - The company has implemented a new procurement strategy that is expected to reduce costs by 5% annually, improving overall profit margins[49]. - The production model has shifted to a demand-driven approach, allowing for a more efficient response to market needs and reducing excess inventory by 30%[49]. - Quality control measures have been strengthened, ensuring compliance with GMP standards, which is expected to enhance product safety and customer trust[49]. - The company has outlined a strategy for mergers and acquisitions to bolster its market position and expand its operational capabilities[135]. - Future guidance indicates a cautious outlook with expected revenue growth of 5% to 7% for the upcoming fiscal year[200]. Legal and Compliance Issues - The company reported a significant litigation case involving a contract dispute with Guangdong Haiwang Pharmaceutical Group, with an amount of CNY 112.8 million at stake[112]. - The company is involved in ongoing litigation with a claim amounting to CNY 208.37 million, with a first-instance judgment already issued[112]. - The company has incurred legal fees of CNY 800,000 related to the aforementioned litigation[112]. - The company has committed to maintaining independence in operations, finance, and assets to avoid competition issues with its controlling shareholder, New China International Group, for a period of five years following the acquisition completion[105]. - The company reported that it will resolve any competition issues with its subsidiaries within one year after the original commitment expires, specifically by March 12, 2026[105]. - The company has pledged to minimize related party transactions to protect the interests of public shareholders and will disclose unavoidable transactions transparently[105]. - The company has not experienced any bankruptcy restructuring matters during the reporting period[111]. - The company is currently addressing competition issues related to its subsidiaries, with a plan to resolve these by March 12, 2026[112]. Community Engagement and Corporate Social Responsibility - The company organized a "Love Assistance for Farmers" initiative to help local farmers increase their income through group purchases of local specialty agricultural products[103]. - Employees participated in a blood donation campaign, contributing a total of 15,800 milliliters to alleviate blood bank pressure[103]. - The company actively engages in community health initiatives, conducting over 40 health education and free clinic events benefiting thousands[103]. Management and Governance - The company has appointed new executives, including a new general manager and several vice presidents, due to personnel changes[97]. - The company has undergone significant management changes, with multiple resignations and appointments in key positions[97]. - The company has not disclosed a market value management system or valuation enhancement plan[95]. - The company has implemented a "Quality and Return Dual Improvement" action plan but has not disclosed its details[95].

天眼查商业履历信息显示，海南海药股份有限公司，成立于1992年，位于海口市，是一家以从事医药制 造业为主的企业。企业注册资本129736.5126万人民币，实缴资本129736.5126万人民币。公司法定代表 人为王建平。 通过天眼查大数据分析，海南海药股份有限公司共对外投资了35家企业，参与招投标项目15次，知识产 权方面有商标信息18条，专利信息5条，此外企业还拥有行政许可81个。 来源：金融界 金融界消息 截至2025年8月25日收盘，海南海药（000566）报收于6.2元，下跌0.32%，换手率3.32%， 成交量38.67万手，成交金额2.39亿元。 资金流向方面，今日主力资金净流出2270.70万元，占比成交额9.51%。其中，超大单净流出529.28万 元、占成交额2.22%，大单净流出1741.42万元、占成交额7.29%，中单净流出流出507.66万元、占成交 额2.13%，小单净流入2778.36万元、占成交额11.63%。 海南海药最新一期业绩显示，截至2025一季报，公司营业总收入2.07亿元、同比减少43.09%，归属净利 润6836.55万元，同比减少331.54%，扣非净利润79 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-051 海南海药股份有限公司 关于持股 5%以上股东部分股份被司法拍卖的提示性公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要内容提示： 1、本次司法拍卖标的为公司持股 5%以上股东深圳市南方同正投资有限公司 （以下简称"南方同正"）所持海南海药股份有限公司（以下简称"公司"或"海 南海药"）已质押的 123,825,900 股股票，占其所持公司全部股份的 92.86%， 占公司总股本的 9.54%。如本次其所涉司法拍卖股份全部拍卖成功，南方同正持 有公司的股份将减少至 9,520,418 股，占公司总股本的 0.73%。 2、南方同正不属于公司控股股东、实际控制人，本次拍卖事项不会导致公 司实际控制权变更，亦不会对公司生产、经营造成不利影响。 3、本次拍卖事项尚处于公示阶段，后续可能涉及竞拍、流拍、缴款、股权 变更过户等环节，拍卖结果存在不确定性。 一、股东股份将被拍卖的基本情况 公司于近日通过公开渠道查询获悉，湖北省武汉市中级人民法院（以下简称 "武汉中院"）拟于 2025 年 9 月 ...

关于持股 5%以上股东部分股份被司法拍卖的提示性公告 证券代码：000566 证券简称：海南海药 公告编号：2025-051 海南海药股份有限公司 深圳市南方同 否 12,382.59 92.86% 9.54% 是（首发后 2025年9月22日10时 武汉中 因 合同纠 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要内容提示： （以下简称"南方同正"）所持海南海药股份有限公司（以下简称"公司"或"海 南海药"）已质押的 123,825,900 股股票，占其所持公司全部股份的 92.86%， 占公司总股本的 9.54%。如本次其所涉司法拍卖股份全部拍卖成功，南方同正持 有公司的股份将减少至 9,520,418 股，占公司总股本的 0.73%。 司实际控制权变更，亦不会对公司生产、经营造成不利影响。 变更过户等环节，拍卖结果存在不确定性。 一、股东股份将被拍卖的基本情况 公司于近日通过公开渠道查询获悉，湖北省武汉市中级人民法院（以下简称 "武汉中院"）拟于 2025 年 9 月 22 日 10 时至 2025 年 9 月 23 日 10 时止（延时 除外）在京 ...

Core Viewpoint - Hainan Haiyao's stock price decreased by 1.27% to 6.20 yuan on August 13, with a trading volume of 450,581 hands and a transaction amount of 279 million yuan [1] Company Overview - Hainan Haiyao operates in the chemical pharmaceutical industry, focusing on drug research, production, and sales. The product line includes antibiotics, anti-tumor drugs, and cardiovascular medications [1] Clinical Development - The company is currently conducting phase II clinical data analysis for Fluorofenone [1] Product Inclusion in National Procurement - Three of the company's drugs, including injectable Cefazolin Sodium, Rosuvastatin Capsules, and Desloratadine Oral Solution, have been included in the National Medical Insurance Administration's 11th batch of centralized procurement [1] Capital Flow - On August 13, the net outflow of main funds was 29.35 million yuan, with a cumulative net outflow of 97.31 million yuan over the past five days [1]

Group 1 - The company is currently conducting data analysis for the Phase II clinical trial of Fluorofenone [1] - Investors are advised to pay attention to the relevant announcements disclosed by the company regarding the clinical trial report [1]

天眼查商业履历信息显示，海南海药股份有限公司，成立于1992年，位于海口市，是一家以从事医药制 造业为主的企业。企业注册资本129736.5126万人民币，实缴资本129736.5126万人民币。公司法定代表 人为王建平。 通过天眼查大数据分析，海南海药股份有限公司共对外投资了35家企业，参与招投标项目15次，知识产 权方面有商标信息18条，专利信息5条，此外企业还拥有行政许可82个。 来源：金融界 金融界消息 截至2025年8月12日收盘，海南海药（000566）报收于6.28元，下跌0.95%，换手率2.9%， 成交量33.83万手，成交金额2.13亿元。 资金流向方面，今日主力资金净流出3134.57万元，占比成交额14.71%。其中，超大单净流出2118.89万 元、占成交额9.94%，大单净流出1015.68万元、占成交额4.77%，中单净流出流入383.06万元、占成交 额1.8%，小单净流入2751.51万元、占成交额12.91%。 海南海药最新一期业绩显示，截至2025一季报，公司营业总收入2.07亿元、同比减少43.09%，归属净利 润6836.55万元，同比减少331.54%，扣非净利润7 ...

Group 1 - As of August 8, 2025, Hainan Haiyao's stock price is 6.32 yuan, with an increase of 0.01 yuan, representing a rise of 0.16% from the previous trading day [1] - The trading volume on that day was 263,462 hands, with a total transaction amount of 166 million yuan [1] - The company's current total market capitalization is 8.199 billion yuan, and the circulating market capitalization is 7.369 billion yuan [1] Group 2 - On August 8, the net inflow of main funds was 4.2386 million yuan, but over the past five days, the overall trend has shown a net outflow of 75.777 million yuan [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-shares is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanzha from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]